AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ...

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...

Drug now approved for four conditions across different inflammatory diseases Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with ...

AbbVie ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...